Harmony Biosciences LLC has uploaded two posters with data on the efficacy and safety of WAKIX (pitolisant) to the American Academy of Neurology (AAN) Science Highlights virtual platform. The abstracts of these posters are also included in an online supplement of the journal Neurology in the “Sleep Medicine: Focus on Therapies 2” poster session.
“We are pleased to have an opportunity to share these important data via this innovative approach with the broader neurology community,” says Harmony’s chief medical officer Jeffrey Dayno, MD, in a release. “These data on the efficacy and safety of WAKIX strengthen the body of scientific evidence that supports WAKIX as a potential treatment option for adult patients living with narcolepsy.”
The data posted by Harmony on AAN’s Science Highlights virtual platform include:
Efficacy of Pitolisant in Patients with High Burden of Narcolepsy Symptoms. Davis, L Krahn, B Vaughn, M Thorpy.
Results from a post-hoc analysis evaluating the efficacy of pitolisant in patients with a high burden of narcolepsy symptoms. Data were pooled from two randomized, placebo-controlled, seven- and eight-week studies of pitolisant in adults with narcolepsy.
Safety and Tolerability of Pitolisant in the Treatment of Adult Patients With Narcolepsy: An Open-Label Expanded Access Program in the United States. E Bauer, C Davis, A Patroneva, J Dayno, M Thorpy.
Results from the final data analysis of the Pitolisant Expanded Access Clinical Evaluation (PEACE) Program, which provided adult patients in the United States. living with narcolepsy access to treatment with pitolisant before its approval by the US Food and Drug Administration.
